FDA accepts Neon Therapeutics’ IND for cancer vaccine NEO-PV-01
NEO-PV-01 is a personalized vaccine designed specifically for each patient based on the neoantigen mutations unique to that patient’s tumor DNA. The IND enables Neon Therapeutics to initiate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.